Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.035
  • Today's Change0.001 / 2.94%
  • Shares traded34.18k
  • 1 Year change-53.33%
  • Beta0.5643
Data delayed at least 20 minutes, as of Feb 10 2026 22:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Key statistics

As of last trade, Syntara Ltd (SNT:ASX) traded at 0.035, 52.17% above the 52 week low of 0.023 set on Sep 26, 2025.
52-week range
Today
0.023Sep 26 20250.095Feb 18 2025
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open0.035
High0.035
Low0.035
Bid0.035
Offer0.036
Previous close0.034
Average volume1.16m
Shares outstanding1.63bn
Free float1.16bn
P/E (TTM)--
Market cap57.16m AUD
EPS (TTM)-0.0084
AUD
Data delayed at least 20 minutes, as of Feb 10 2026 22:59 GMT.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.